- Molecular NameGanciclovir
- SynonymGA2; ganciclovir; Ganciclovir Sodium
- Weight254.246
- Drugbank_IDDB01004
- ACS_NO82410-32-0
- Show 2D model
- LogP (experiment)-2.1
- LogP (predicted, AB/LogP v2.0)-1.36
- pka2.2, 9.4
- LogD (pH=7, predicted)-1.48
- Solubility (experiment)4.3 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.0
- LogSw (predicted, AB/LogsW2.0)0.54
- Sw (mg/ml) (predicted, ACD/Labs)0.25
- No.of HBond Donors5
- No.of HBond Acceptors8
- No.of Rotatable Bonds5
- TPSA122.1
- StatusFDA approved
- AdministrationIV, oral, intravitreal
- PharmacologyAn antiviral medication used to treat or prevent cytomegalovirus (CMV) infections.
- Absorption_value4.0
- Absorption (description)Ganciclovir is poorly absorbed after oral administration; peak plasma concentrations are reached after about 2 to 4 h.
- Caco_2-6.27
- Bioavailability4.0
- Protein binding1.5
- Volume of distribution (VD)1.1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmGuanylate kinase (CMV UL97 gene product)
- Half life3.7 h
- ExcretionThe drug is excreted unchanged in the urine by glomerular filtration and active tubular secretion; approx. 90% of an oral dose is excreted in urine within 24 h of administration. With an intravenous dose, on the other hand, the majority is excreted in faeces. Haemodialysis reduces plasma concentrations by about 50%. Ganciclovir does not accumulate in plasma after repeated dosing.
- Urinary Excretion91
- Clerance3.4 ml/min/kg
- ToxicityThe trough serum toxic concentration is 3 to 5 mg/L and peak, 20 mg/L. Symptoms of overdose include irreversible pancytopenia, worsening GI symptoms, and acute renal failure. Suspected cancer agent.
- LD50 (rat)N/A
- LD50 (mouse)LD50: > 2g/kg